Evidence map›Paper›PMID 33303710›Full record

ArticleAnnals of laboratory medicine2021

Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma.

Min Young Lee, Chan-Jeoung Park, Young-Uk Cho, Eunkyoung You, Seongsoo Jang, Eul Ju Seo, Jung-Hee Lee, Dok Hyun Yoon, Cheolwon Suh

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of laboratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Min Young LeeDepartment of Laboratory Medicine, Kyung Hee University School of Medicine and Kyung Hee University Hospital, Gangdong, Seoul, Korea.ORCID https://orcid.org/0000-0001-8435-7581
Chan-Jeoung ParkDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-4396-8348
Young-Uk ChoDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4403-8989
Eunkyoung YouDepartment of Laboratory Medicine, Inje University College of Medicine, Busan Baik Hospital, Busan, Korea.ORCID https://orcid.org/0000-0002-6836-499X
Seongsoo JangDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0045-1747
Eul Ju SeoDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8247-3746
Jung-Hee LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-3127-0068
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8289-3548
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9178-4431
Ulsan College · KRKyung Hee University Hospital at Gangdong · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM.

methodsA total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry.

resultsAt diagnosis, the median PD-1 expression on CD4

conclusionsPD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities.

Indexed as

Multiple MyelomaProgrammed Cell Death 1 ReceptorApoptosis Regulatory ProteinsBone MarrowCD8-Positive T-LymphocytesFemaleHumansMaleT-Lymphocyte SubsetsApoptosis Regulatory ProteinsProgrammed Cell Death 1 ReceptorFlow cytometryImmune checkpoint programmed cell death protein-1 (PD-1)Plasma cell myelomaT cell subset

Identifiers

PMID33303710
PMCPMC7748102
OpenAlexW3111659153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.